FRα expression in high-grade serous ovarian cancer (FRα positive)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-country, retrospective biomarker study using FFPE tissue samples from about 200 women diagnosed between 2001 and 2025. Samples collected at initial diagnosis will be analyzed centrally with the Ventana FOLR1 RxDx assay to determine FRα expression. The primary goal is to determine the prevalence of FRα positivity, defined as at least 75% viable tumor cells showing moderate to strong membrane staining. Secondary analyses are not specified in the available description. Patients included are adults with high-grade serous epithelial ovarian cancer and adequate tissue; samples from relapsed disease are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients.
* 18 years of age or older.
* Patients diagnosed with high-grade serous epithelial ovarian cancer according to pathologists' report.

Exclusion Criteria:

* Diagnosis of non-epithelial ovarian tumors
* Diagnosis of endometrioid, mucinous, or clear cell carcinomas.
* Inadequate (poor quality or inadequate posology for analysis) tissue samples.

Where it's running

• Hellenic Cooperative Oncology Group
  Athens, Greece Recruiting

Study contacts

• Study coordinator: Elena Fountzila
• Email: fountzila@oncogenome.gr
• Phone: +306945779709

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Idetrexed plus olaparib for high-grade serous ovarian cancer

  This trial tests whether combining idetrexed and olaparib helps people with high-grade serous ovarian cancer that is resistant to standard treatments.

  Recruiting Phase 1 Institute of Cancer Research, United Kingdom · Cambridge, Cambridgeshire and 2 other locations · NCT06976892

• Investigating the Role of RPL8 Protein in Ovarian Cancer

  This study is trying to see if the RPL8 protein in ovarian cancer tumors can help doctors understand the disease better and make more informed treatment choices for patients.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT06777082

• Exploring Tumor Biology in Ovarian Cancer with Advanced Imaging Techniques

  This study is testing new imaging techniques to better understand ovarian cancer tumors and improve personalized treatment for patients.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier · NCT06084195

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.